ImmunityBio, Inc.

ImmunityBio, Inc.

164.00
MXN
0.00
(0.00%)
-19.42EPS
Mar 02Next Earn

Important Dates

ImmunityBio Inc's next confirmed earnings release is scheduled for March 2, 2027.

Earnings Date3/2/2027

Share Statistics

As of September 30, 2026, ImmunityBio Inc has 1.06B shares outstanding.

Shares Outstanding1.06B

Financial Position

As of September 30, 2026, ImmunityBio Inc maintains a current ratio of 4.27, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -75.91, indicating conservative leverage, while an interest coverage ratio of -2.17 demonstrates limited ability to service its debt obligations.

Current Ratio4.27
Quick Ratio3.96
Debt / Equity-75.91
Debt / EBITDA-3.38
Interest Coverage-2.17

Financial Efficiency

MXN

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -196.68, reflecting losses generated across the asset base. The company generates approximately 4.77M in revenue per employee across its workforce of 691.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.66 indicates how many times ImmunityBio Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-196.68
Revenue Per Employee4.77M
Employee Count691.00
Inventory Turnover0.66

Taxes

MXN

Over the twelve months ended September 30, 2026, ImmunityBio Inc recorded an income tax benefit of -2.28M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -20.04B and -20.04B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-2.28M

Income Statement

MXN

Over the twelve months ended September 30, 2026, ImmunityBio Inc generated 3.30B in revenue and converted that into -20.04B in net income, yielding earnings per share of -19.42. EBITDA reached -4.65B, while operating income came in at -4.95B.

Revenue3.30B
Gross Profit3.26B
Operating Income-4.95B
Pretax Income-20.04B
Net Income-20.04B
EBITDA-4.65B
EBIT-4.95B
Earnings Per Share (EPS)-19.42

Balance Sheet

MXN

As of September 30, 2026, ImmunityBio Inc holds 6.04B in cash and equivalents against 15.70B in total debt, resulting in a net debt position of 14.26B. Total book value stands at -20.70B, with working capital of 5.79B providing operational flexibility.

Cash & Cash Equivalents6.04B
Total Debt15.70B
Net Debt14.26B
Equity (Book Value)-20.70B
Book Value Per Share-19.46
Working Capital5.79B

Cash Flow

MXN

ImmunityBio Inc produced -5.19B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -172.05M in capital expenditures, free cash flow totaled -5.36B - equivalent to -5.20 per share.

Operating Cash Flow-5.19B
Capital Expenditures-172.05M
Free Cash Flow-5.36B
FCF Per Share-5.20

Margins

Over the twelve months ended September 30, 2026, ImmunityBio Inc posted a gross margin of 98.79, reflecting its pricing power and cost economics. The operating margin of -150.16 and net profit margin of -607.79 provide insight into operational efficiency.

Gross Margin98.79
Operating Margin-150.16
Pretax Margin-607.89
Profit Margin-607.79
EBITDA Margin-141.10